A Phase 3 interventional study of 80 mg ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 16th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 23rd largest by enrollment, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
Drug: 80 mg ixekizumab
Administered SC
Also known as: LY2439821
Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week (Wk) 12
Percentage of Participants Achieving ≥75% Improvement in PASI
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region, the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Wks 24 and 52
Pharmacokinetics (PK): Ctrough at Steady State (Ctrough ss) of Ixekizumab
PK samples were from 1 or 2 sampling cohorts. Ctrough is the minimum observed concentration of ixekizumab at steady state. Steady-state ixekizumab trough concentrations were summarized for the induction dosing period at week 12, the time of the primary efficacy assessment. Steady-state ixekizumab trough concentrations were summarized for the maintenance dosing period at week 24.
Time frame: Pre-dose at Wks 12 (Day 84) and Wks24 (Day 168)
Number of Participants With Anti-Ixekizumab Antibodies
Treatment-emergent immunogenicity is defined as any occurrence of a 4-fold or 2-dilution increase in titer over the pretreatment baseline titer. In the case of a negative result at baseline, treatment-emergent immunogenicity is defined as an increase in titer to ≥1:10.
Time frame: Baseline through Wk 52
Percent of Participants Achieving PASI 90% and 100% Improvement
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Wks 12, 24 and 52
Percentage of Participants With Static Physician Global Assessment (sPGA) (0 or 1) or sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: sPGA)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).
Time frame: Wks 12, 24 and 52
Change From Baseline in Percent of Body Surface Area (BSA) Involvement
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from range 0 to 80. Higher scores indicated more severe psoriasis.
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Change From Baseline in Psoriasis Scalp Severity Index (PSSI)
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Change From Baseline in Itch Numeric Rating Scale (NRS) Score
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Change From Baseline in Dermatology Life Quality Index (DLQI) Score
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point increase in total score from baseline is considered clinically relevant.
Time frame: Baseline, Wk 12; Baseline, Wk 24; Baseline, Wk 52
Number of Participants Achieving American College of Rheumatology 20% (ACR20) Improvement [Efficacy of Ixekizumab in Participants With Psoriatic Arthritis (PsA) as Measured by ACR20]
ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain visual analog scale (VAS), Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR).
Time frame: Wks 12, 24 and 52
Change From Baseline in Participants Assessment of Joint Pain Visual Analog Scale (VAS) (Efficacy of Ixekizumab in Participants With PsA Pain VAS)
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine).
Time frame: Baseline, Wk 12; Baseline, Wk 52
Percent of Participants Achieving PASI 75%, 90% and/or 100% Improvement
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated: 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling, with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Wk 100 and Retreatment Wk 192
Percentage of Participants With sPGA (0 or 1) and sPGA (0)
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).
Time frame: Wk 100 and Retreatment Wk 192
Change From Baseline in Percent of BSA Involvement
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in NAPSI
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all the fingernails equals the total NAPSI score with a range 0 to 80. Higher scores indicate more severe psoriasis.
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in PSSI
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in QIDS-SR16 Score
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst) scale. The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in Itch NRS Score
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10, (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in DLQI Score
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher scores indicating greater quality of life impairment. A 5-point increase in total score from baseline is considered clinically relevant.
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Change From Baseline in Participants Assessment of Joint Pain VAS
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine).
Time frame: Baseline, Wk 100; Baseline, Retreatment Wk 192
Number of Participants Achieving ACR20
ACR20 response is defined as ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain VAS, Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the HAQ-DI, or CRP or the ESR. Analysis population included participants with PsA who had 3 or more tender joints and 3 or more swollen joints at screening and baseline.
Time frame: Wk 100 and Wk Retreatment Wk 192
Period 2-Induction Dosing Period (Weeks 0 up to 12), Period 3-Maintenance Dosing Period (Weeks 12 up to 52), Period 4-Drug Free Period (Weeks 52 up to 100), Period 5-Retreatment Period (up to 192 additional weeks) and Period 6-Post-Treatment Follow-Up Period up to 12 weeks after the last visit.
| Milestone | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Started | 91 |
| Received at least 1 dose of study drug | 91 |
| Erythrodermic psoriasis (ps) | 8 |
| Pustular ps | 5 |
| Plaque ps | 78 |
| Completed | 90 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Started | 90 |
| Received at least 1 dose of study drug | 90 |
| Completed | 83 |
| Not completed | 7 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Milestone | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Started | 70 |
| Adverse event | 1 |
| Physician decision | 1 |
| Completed | 9 |
| Not completed | 61 |
| Withdrew: Relapsed | 61 |
| Milestone | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Started | 80 |
| Completed | 70 |
| Not completed | 10 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Milestone | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Started | 88 |
| Completed | 79 |
| Not completed | 9 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 3 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI) | 98.7 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region, the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 24 | 95.9 |
| Wk 52 | 92.3 |
PK samples were from 1 or 2 sampling cohorts. Ctrough is the minimum observed concentration of ixekizumab at steady state. Steady-state ixekizumab trough concentrations were summarized for the induction dosing period at week 12, the time of the primary efficacy assessment. Steady-state ixekizumab trough concentrations were summarized for the maintenance dosing period at week 24.
| micrograms/milliliter (µg/mL) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) Cohort 2 | 9.63 ± 43.6 |
| Wk 24 (80 mg Q4W) Cohort 1 | 3.48 ± 65.4 |
Treatment-emergent immunogenicity is defined as any occurrence of a 4-fold or 2-dilution increase in titer over the pretreatment baseline titer. In the case of a negative result at baseline, treatment-emergent immunogenicity is defined as an increase in titer to ≥1:10.
| participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Plaque Ps | 10 |
| Erythrodermic Ps | 0 |
| Pustular Ps | 0 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) PASI 90% | 83.3 |
| Wk 12 (80 mg Q2W) PASI 100% | 32.1 |
| Wk 24 (80 mg Q4W) PASI 90% | 90.5 |
| Wk 24 (80 mg Q4W) PASI 100% | 48.6 |
| Wk 52 (80 mg Q4W) PASI 90% | 80.8 |
| Wk 52 (80 mg Q4W) PASI 100% | 48.7 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) sPGA (0 or 1) | 89.7 |
| Wk 24 (80 mg Q4W) sPGA (0 or 1) | 89.2 |
| Wk 52 (80 mg Q4W) sPGA (0 or 1) | 83.3 |
| Wk 12 (80 mg Q2W) sPGA (0) | 35.9 |
| Wk 24 (80 mg Q4W) sPGA (0) | 51.4 |
| Wk 52 (80 mg Q4W) sPGA (0) | 52.6 |
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).
| percentage of BSA | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -38.3 ± 19.26 |
| Wk 24 (80 mg Q4W) | -41.2 ± 20.23 |
| Wk 52 (80 mg Q4W) | -40.8 ± 19.73 |
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from range 0 to 80. Higher scores indicated more severe psoriasis.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -7.7 ± 14.65 |
| Wk 24 (80 mg Q4W) | -20.5 ± 19.42 |
| Wk 52 (80 mg Q4W) | -23.4 ± 23.67 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -24.8 ± 15.12 |
| Wk 24 (80 mg Q4W) | -24.9 ± 15.11 |
| Wk 52 (80 mg Q4W) | -23.3 ± 16.48 |
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -1.1 ± 3.65 |
| Wk 24 (80 mg Q4W) | -1.6 ± 3.80 |
| Wk 52 (80 mg Q4W) | -1.4 ± 3.57 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -4.7 ± 2.68 |
| Wk 24 (80 mg Q4W) | -4.8 ± 2.90 |
| Wk 52 (80 mg Q4W) | -4.8 ± 2.83 |
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point increase in total score from baseline is considered clinically relevant.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -9.2 ± 5.75 |
| Wk 24 (80 mg Q4W) | -9.2 ± 6.57 |
| Wk 52 (80 mg Q4W) | -9.6 ± 6.24 |
ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain visual analog scale (VAS), Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR).
| participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | 4 |
| Wk 24 (80 mg Q4W) | 4 |
| Wk 52 (80 mg Q4W) | 5 |
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine).
| mm | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 12 (80 mg Q2W) | -47.3 ± 22.05 |
| Wk 52 (80 mg Q4W) | -51.0 ± 19.05 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated: 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling, with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 100, PASI 75 | 7.5 |
| Wk 100, PASI 90 | 3.0 |
| Wk 100, PASI 100 | 0 |
| Wk 192, PASI 75 | 0 |
| Wk 192, PASI 90 | 0 |
| Wk 192, PASI 100 | 0 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).
| percentage of participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 100, sPGA(0, 1) | 4.5 |
| Wk 100, sPGA(0) | 0 |
| Wk 192, sPGA(0, 1) | 0 |
| Wk 192, sPGA(0) | 0 |
BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).
| percentage of BSA | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -24.7 ± 17.32 |
| Baseline, Wk 192 | -40.2 ± 21.18 |
The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all the fingernails equals the total NAPSI score with a range 0 to 80. Higher scores indicate more severe psoriasis.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -16.8 ± 19.87 |
| Baseline, Wk 192 | -21.4 ± 26.31 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -8.5 ± 16.16 |
| Baseline, Wk 192 | -23.2 ± 15.17 |
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst) scale. The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -0.5 ± 4.02 |
| Baseline, Wk 192 | -1.8 ± 3.87 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10, (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -1.1 ± 2.62 |
| Baseline, Wk 192 | -4.9 ± 2.59 |
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher scores indicating greater quality of life impairment. A 5-point increase in total score from baseline is considered clinically relevant.
| units on a scale | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -2.3 ± 4.83 |
| Baseline, Wk 192 | -8.9 ± 5.70 |
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine).
| mm | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Baseline, Wk 100 | -12.8 ± 39.59 |
| Baseline, Wk 192 | -43.8 ± 25.66 |
ACR20 response is defined as ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain VAS, Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the HAQ-DI, or CRP or the ESR. Analysis population included participants with PsA who had 3 or more tender joints and 3 or more swollen joints at screening and baseline.
| Participants | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Wk 100 | 0 |
| Wk 192 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2439821 80mg-Combined Induction and Maintenance Periods | — | 4/91 (4.4%) | 61/91 (67%) |
| LY2439821 80mg-Drug-Free Period | — | 3/70 (4.3%) | 18/70 (25.7%) |
| LY2439821 80mg-Retreatment Period | — | 9/80 (11.3%) | 52/80 (65%) |
| LY2439821 80mg-Post-Treatment Follow-Up Period | — | 0/88 (0%) | 2/88 (2.3%) |
| Event | LY2439821 80mg-Combined Induction and Maintenance Periods | LY2439821 80mg-Drug-Free Period | LY2439821 80mg-Retreatment Period | LY2439821 80mg-Post-Treatment Follow-Up Period |
|---|---|---|---|---|
| Cytomegalovirus infectionInfections and infestations | 0/91 | 1/70 | 0/80 | 0/88 |
| Hand fractureInjury, poisoning and procedural complications | 0/91 | 1/70 | 1/80 | 0/88 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/91 | 1/70 | 0/80 | 0/88 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 0/91 | 0/70 | 1/80 | 0/88 |
| Large intestine polypGastrointestinal disorders | 0/91 | 0/70 | 1/80 | 0/88 |
| CholelithiasisHepatobiliary disorders | 1/91 | 0/70 | 1/80 | 0/88 |
| Hyperplastic cholecystopathyHepatobiliary disorders | 0/91 | 0/70 | 1/80 | 0/88 |
| PharyngotonsillitisInfections and infestations | 0/91 | 0/70 | 1/80 | 0/88 |
| PneumoniaInfections and infestations | 0/91 | 0/70 | 1/80 | 0/88 |
| Ankle fractureInjury, poisoning and procedural complications | 0/91 | 0/70 | 1/80 | 0/88 |
| Event | LY2439821 80mg-Combined Induction and Maintenance Periods | LY2439821 80mg-Drug-Free Period | LY2439821 80mg-Retreatment Period | LY2439821 80mg-Post-Treatment Follow-Up Period |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 36/91 | 6/70 | 16/80 | 0/88 |
| EczemaSkin and subcutaneous tissue disorders | 11/91 | 1/70 | 10/80 | 0/88 |
| InfluenzaInfections and infestations | 2/91 | 3/70 | 9/80 | 0/88 |
| Eczema asteatoticSkin and subcutaneous tissue disorders | 3/91 | 0/70 | 9/80 | 0/88 |
| Injection site reactionGeneral disorders | 8/91 | 0/70 | 2/80 | 0/88 |
| Seborrhoeic dermatitisSkin and subcutaneous tissue disorders | 8/91 | 0/70 | 1/80 | 0/88 |
| UrticariaSkin and subcutaneous tissue disorders | 8/91 | 3/70 | 3/80 | 0/88 |
| Hepatic function abnormalHepatobiliary disorders | 0/91 | 1/70 | 7/80 | 0/88 |
| FolliculitisInfections and infestations | 3/91 | 2/70 | 7/80 | 0/88 |
| HypertensionVascular disorders | 1/91 | 0/70 | 7/80 | 0/88 |
All enrolled participants.
| Age, Continuous(years) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Mean | 46.2 ± 11.89 |
| Sex: Female, Male(Participants) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Female | 21 |
| Male | 70 |
| Ethnicity (NIH/OMB)(Participants) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 91 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 91 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Japan | 91 |
| Psoriasis Area and Severity Index (PASI) Total Score(units on a scale) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Mean | 27.24 ± 10.545 |
| Static Physician Global Assessment (sPGA) Score(participants) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| 0: Clear | 0 |
| 1: Minimal | 0 |
| 2: Mild | 1 |
| 3: Moderate | 26 |
| 4: Severe | 53 |
| 5: Very Severe | 11 |
| Percentage (%) of Body Surface Area (BSA)(units on a scale) | 80 mg Ixekizumab (LY2439821) |
|---|---|
| Mean | 45.5 ± 23.22 |
6 further baseline measures are reported on the registry.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Jun 2012, a primary completion of Sep 2013 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 3 years after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab